[Distribution studies of 111In labeled bleomycin in the intratumoral and peritumoral treatment of advanced squamous cell carcinomas in the oto-rhino-larygnological region (author's transl)].
The localization of 111In labeled Bleomycin was studied in 9 patients with advanced squamous cell carcinomas. The dosis was injected either peritumorally or intramorally. Accumulation of Radiobleomycin in tumor tissue, in blood and in urine was tested. We found a very high accumulation in tumor tissue for a short time within 2 hours, a very rapid excretion of Radiobleomycin in urine and concomitant slowly decrease of 111In Bleomycin in blood was observed.
D001761:Bleomycin / Q000008:administration & dosage* / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D006801:Humans; D007204:Indium; D007700:Kinetics; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy* / Q000378:metabolism; D011868:Radioisotopes
D011868:Radioisotopes; D007204:Indium; D001761:Bleomycin
Pharmakokinetische Untersuchungen nach intra- und peritumo-aler Applikation von wässriger Bleomycinlösung bei Tumoren im HNO-Bereich.